ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

518
Analysis
Health Care • China
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
•25 Jan 2021 09:52

China Healthcare Weekly (Jan.22)

The article analyzed the new official document for the volume-based purchase,industry viewpoints on China cryogenic storage market and ā€œAI +...

Logo
369 Views
Share
•18 Jan 2021 09:32

China Healthcare Weekly (Jan.15)

This article analyzed the newĀ interim procedures released by NHSA, trend of blood products and biological drug market, and also include company...

Logo
530 Views
Share
bullish•Man Wah Holdings
•14 Jan 2021 20:13

Man Wah Placement - Riding High on Planned Store Expansion

Man Wah Holdings (1999 HK) plans to raise around US$260m to expand manufacturing facilities in China and open new stores. The stock has nearly...

Logo
556 Views
Share
•14 Jan 2021 19:04

Innovent Biologics Placement - Momentum Is Very Strong but past Deals Have Been Mixed

Innovent Biologics Inc (1801 HK) is looking to raise about U$600m to fund its clinical trialsĀ  and product licensing and possible M&A. This will be...

Logo
545 Views
Share
bullish•BeiGene
•13 Jan 2021 02:26

BeiGene: Novartis Grabs Tislelizumab Rights

BeiGene's deal with Novartis for PD-1 tislelizumab validates its competitive position, and marks a rising trend of Chinese companies licensing...

Share
x